Literature DB >> 33468237

Aglycemic growth enhances carbohydrate metabolism and induces sensitivity to menadione in cultured tumor-derived cells.

Cameron A Schmidt1,2, Kelsey L McLaughlin1,2, Ilya N Boykov1,2, Rafiq Mojalagbe1, Arthi Ranganathan1, Katherine A Buddo1,2, Chien-Te Lin1,2, Kelsey H Fisher-Wellman3,4, P Darrell Neufer5,6.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the most prevalent form of liver malignancy and carries poor prognoses due to late presentation of symptoms. Treatment of late-stage HCC relies heavily on chemotherapeutics, many of which target cellular energy metabolism. A key platform for testing candidate chemotherapeutic compounds is the intrahepatic orthotopic xenograft (IOX) model in rodents. Translational efficacy from the IOX model to clinical use is limited (in part) by variation in the metabolic phenotypes of the tumor-derived cells that can be induced by selective adaptation to subculture conditions.
METHODS: In this study, a detailed multilevel systems approach combining microscopy, respirometry, potentiometry, and extracellular flux analysis (EFA) was utilized to examine metabolic adaptations that occur under aglycemic growth media conditions in HCC-derived (HEPG2) cells. We hypothesized that aglycemic growth would result in adaptive "aerobic poise" characterized by enhanced capacity for oxidative phosphorylation over a range of physiological energetic demand states.
RESULTS: Aglycemic growth did not invoke adaptive changes in mitochondrial content, network complexity, or intrinsic functional capacity/efficiency. In intact cells, aglycemic growth markedly enhanced fermentative glycolytic substrate-level phosphorylation during glucose refeeding and enhanced responsiveness of both fermentation and oxidative phosphorylation to stimulated energy demand. Additionally, aglycemic growth induced sensitivity of HEPG2 cells to the provitamin menadione at a 25-fold lower dose compared to control cells.
CONCLUSIONS: These findings indicate that growth media conditions have substantial effects on the energy metabolism of subcultured tumor-derived cells, which may have significant implications for chemotherapeutic sensitivity during incorporation in IOX testing panels. Additionally, the metabolic phenotyping approach used in this study provides a practical workflow that can be incorporated with IOX screening practices to aid in deciphering the metabolic underpinnings of chemotherapeutic drug sensitivity.

Entities:  

Keywords:  Cancer; Confocal microscopy; Galactose; Glycolysis; HEPG2; Mitochondria; Oroboros; Oxidative phosphorylation; Seahorse xf24

Year:  2021        PMID: 33468237      PMCID: PMC7816515          DOI: 10.1186/s40170-021-00241-0

Source DB:  PubMed          Journal:  Cancer Metab        ISSN: 2049-3002


  75 in total

1.  Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines.

Authors:  Luigi Fiume; Marcella Manerba; Marina Vettraino; Giuseppina Di Stefano
Journal:  Pharmacology       Date:  2010-08-10       Impact factor: 2.547

2.  Selective attenuation of metabolic branch of insulin receptor down-signaling by high glucose in a hepatoma cell line, HepG2 cells.

Authors:  K Nakajima; K Yamauchi; S Shigematsu; S Ikeo; M Komatsu; T Aizawa; K Hashizume
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

3.  Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts.

Authors:  B H Robinson; R Petrova-Benedict; J R Buncic; D C Wallace
Journal:  Biochem Med Metab Biol       Date:  1992-10

4.  Direct real-time quantification of mitochondrial oxidative phosphorylation efficiency in permeabilized skeletal muscle myofibers.

Authors:  Daniel S Lark; Maria J Torres; Chien-Te Lin; Terence E Ryan; Ethan J Anderson; P Darrell Neufer
Journal:  Am J Physiol Cell Physiol       Date:  2016-06-22       Impact factor: 4.249

5.  Pyruvate and citric acid cycle carbon requirements in isolated skeletal muscle mitochondria.

Authors:  Jeffrey I Messer; Matthew R Jackman; Wayne T Willis
Journal:  Am J Physiol Cell Physiol       Date:  2003-11-05       Impact factor: 4.249

6.  The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death.

Authors:  Laleh Kamalian; Amy E Chadwick; Mark Bayliss; Neil S French; Mario Monshouwer; Jan Snoeys; B Kevin Park
Journal:  Toxicol In Vitro       Date:  2015-03-05       Impact factor: 3.500

7.  Glucose-modulated mitochondria adaptation in tumor cells: a focus on ATP synthase and inhibitor Factor 1.

Authors:  Rossana Domenis; Elena Bisetto; Davide Rossi; Marina Comelli; Irene Mavelli
Journal:  Int J Mol Sci       Date:  2012-02-10       Impact factor: 6.208

8.  NOX1 supports the metabolic remodeling of HepG2 cells.

Authors:  Katharina Bertram; Cristina-Maria Valcu; Michael Weitnauer; Uwe Linne; Agnes Görlach
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

9.  Separation of metabolic supply and demand: aerobic glycolysis as a normal physiological response to fluctuating energetic demands in the membrane.

Authors:  Tamir Epstein; Liping Xu; Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metab       Date:  2014-06-05

10.  Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria.

Authors:  Hannah R Bridges; Andrew J Y Jones; Michael N Pollak; Judy Hirst
Journal:  Biochem J       Date:  2014-09-15       Impact factor: 3.857

View more
  2 in total

1.  Bioenergetic Phenotyping of DEN-Induced Hepatocellular Carcinoma Reveals a Link Between Adenylate Kinase Isoform Expression and Reduced Complex I-Supported Respiration.

Authors:  Kelsey L McLaughlin; Margaret A M Nelson; Hannah S Coalson; James T Hagen; McLane M Montgomery; Ashley R Wooten; Tonya N Zeczycki; Nasreen A Vohra; Kelsey H Fisher-Wellman
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 2.  Cellular Bioenergetics: Experimental Evidence for Alcohol-induced Adaptations.

Authors:  Liz Simon; Patricia E Molina
Journal:  Function (Oxf)       Date:  2022-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.